Publications by Kristine Kleivi Sahlberg

58 publications found

Publications 2024

1. Fjermeros K, Ghannoum S, Geisler SB, Bhargava S, Tahiri A, Klajic J, Lüders T, Fongård M, Nawaz MS, Bosnjak-Olsen T, Buvarp UE, Rosenskiold AKJ, Nguyen NT, Sletbak TT, Seyedzadeh M, Selsås K, Porojnicu AC, Skjerven HK, Hovda T, Sahlberg KK, Torland LA, Lyngra M, Hammarström CL, Hönigsperger EB, Noone JC et al. (2024)
   The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer
   Future Oncol, 20 (32), 2457-2466
   DOI 10.1080/14796694.2024.2377531, PubMed 39073142

Publications 2023

1. Hovda T, Larsen M, Romundstad L, Sahlberg KK, Hofvind S (2023)
   Breast cancer missed at screening; hindsight or mistakes?
   Eur J Radiol, 165, 110913
   DOI 10.1016/j.ejrad.2023.110913, PubMed 37311339
2. Normann LS, Haugen MH, Hongisto V, Aure MR, Leivonen SK, Kristensen VN, Tahiri A, Engebraaten O, Sahlberg KK, Mælandsmo GM (2023)
   High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer
   PLoS One, 18 (1), e0280507
   DOI 10.1371/journal.pone.0280507, PubMed 36706086
3. Skjerven HK, Myklebust EM, Korvald C, Stubberud K, Hovda T, Porojnicu AC, Kaaresen R, Hofvind S, Schlicting E, Sahlberg KK (2023)
   Long-term follow-up of complex oncoplastic breast-conserving surgery, standard breast conservation and skin-sparing mastectomy in DCIS - a register-based study
   Eur J Surg Oncol, 50 (2), 107938
   DOI 10.1016/j.ejso.2023.107938, PubMed 38199004

Publications 2022

1. Bjørklund SS, Aure MR, Häkkinen J, Vallon-Christersson J, Kumar S, Evensen KB, Fleischer T, Tost J, OSBREAC, Sahlberg KK, Mathelier A, Bhanot G, Ganesan S, Tekpli X, Kristensen VN (2022)
   Subtype and cell type specific expression of lncRNAs provide insight into breast cancer
   Commun Biol, 5 (1), 834
   DOI 10.1038/s42003-022-03559-7, PubMed 35982125
2. Normann LS, Haugen MH, Aure MR, Kristensen VN, Mælandsmo GM, Sahlberg KK (2022)
   miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy
   Breast Cancer (Dove Med Press), 14, 25-39
   DOI 10.2147/BCTT.S338404, PubMed 35256859
3. Skjerven HK, Danielsen AS, Schlichting E, Sahlberg KK, Hofvind S (2022)
   Treatment of Ductal Carcinoma in situ: A Register-Based Study of Norwegian Women Diagnosed between 1995 and 2018
   Breast Care (Basel), 17 (5), 486-494
   DOI 10.1159/000524564, PubMed 36684407
4. Skjerven HK, Myklebust EM, Korvald C, Porojnicu AC, Kaaresen R, Hofvind S, Schlicting E, Sahlberg KK (2022)
   Oncological outcomes after simple and skin-sparing mastectomy of ductal carcinoma in situ: A register-based cohort study of 576 Norwegian women
   Eur J Surg Oncol, 49 (3), 575-582
   DOI 10.1016/j.ejso.2022.11.594, PubMed 36509629
5. Wolowczyk C, Neckmann U, Aure MR, Hall M, Johannessen B, Zhao S, Skotheim RI, Andersen SB, Zwiggelaar R, Steigedal TS, Lingjærde OC, Sahlberg KK, Almaas E, Bjørkøy G (2022)
   NRF2 drives an oxidative stress response predictive of breast cancer
   Free Radic Biol Med, 184, 170-184
   DOI 10.1016/j.freeradbiomed.2022.03.029, PubMed 35381325

Publications 2021

1. Aure MR, Fleischer T, Bjørklund S, Ankill J, Castro-Mondragon JA, OSBREAC, Børresen-Dale AL, Tost J, Sahlberg KK, Mathelier A, Tekpli X, Kristensen VN (2021)
   Crosstalk between microRNA expression and DNA methylation drives the hormone-dependent phenotype of breast cancer
   Genome Med, 13 (1), 72
   DOI 10.1186/s13073-021-00880-4, PubMed 33926515
2. Ben-Elazar S, Aure MR, Jonsdottir K, Leivonen SK, Kristensen VN, Janssen EAM, Kleivi Sahlberg K, Lingjærde OC, Yakhini Z (2021)
   miRNA normalization enables joint analysis of several datasets to increase sensitivity and to reveal novel miRNAs differentially expressed in breast cancer
   PLoS Comput Biol, 17 (2), e1008608
   DOI 10.1371/journal.pcbi.1008608, PubMed 33566819
3. Hovda T, Hoff SR, Larsen M, Romundstad L, Sahlberg KK, Hofvind S (2021)
   True and Missed Interval Cancer in Organized Mammographic Screening: A Retrospective Review Study of Diagnostic and Prior Screening Mammograms
   Acad Radiol, 29 Suppl 1, S180-S191
   DOI 10.1016/j.acra.2021.03.022, PubMed 33926794
4. Normann LS, Aure MR, Leivonen SK, Haugen MH, Hongisto V, Kristensen VN, Mælandsmo GM, Sahlberg KK (2021)
   MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro
   Sci Rep, 11 (1), 10893
   DOI 10.1038/s41598-021-90385-2, PubMed 34035375

Publications 2020

1. Hovda T, Tsuruda K, Hoff SR, Sahlberg KK, Hofvind S (2020)
   Radiological review of prior screening mammograms of screen-detected breast cancer
   Eur Radiol, 31 (4), 2568-2579
   DOI 10.1007/s00330-020-07130-y, PubMed 33001307
2. Skjerven HK, Danielsen AS, Schlichting E, Sahlberg KK, Hofvind S (2020)
   Surgical treatment of breast cancer in Norway 2003-2018
   Tidsskr Nor Laegeforen, 140 (15)
   DOI 10.4045/tidsskr.20.0090, PubMed 33118768
3. Tinholt M, Stavik B, Tekpli X, Garred Ø, Borgen E, Kristensen V, Sahlberg KK, Sandset PM, Iversen N (2020)
   Coagulation factor V is a marker of tumor-infiltrating immune cells in breast cancer
   Oncoimmunology, 9 (1), 1824644
   DOI 10.1080/2162402X.2020.1824644, PubMed 33457104

Publications 2019

1. Hovda T, Holen ÅS, Lång K, Albertsen JL, Bjørndal H, Brandal SHB, Sahlberg KK, Skaane P, Suhrke P, Hofvind S (2019)
   Interval and Consecutive Round Breast Cancer after Digital Breast Tomosynthesis and Synthetic 2D Mammography versus Standard 2D Digital Mammography in BreastScreen Norway
   Radiology, 294 (2), 256-264
   DOI 10.1148/radiol.2019191337, PubMed 31821118
2. Johansson HJ, Socciarelli F, Vacanti NM, Haugen MH, Zhu Y, Siavelis I, Fernandez-Woodbridge A, Aure MR, Sennblad B, Vesterlund M, Branca RM, Orre LM, Huss M, Fredlund E, Beraki E, Garred Ø, Boekel J, Sauer T, Zhao W, Nord S, Höglander EK, Jans DC, Brismar H, Haukaas TH, Bathen TF et al. (2019)
   Breast cancer quantitative proteome and proteogenomic landscape
   Nat Commun, 10 (1), 1600
   DOI 10.1038/s41467-019-09018-y, PubMed 30962452
3. Lindholm EM, Leivonen SK, Undlien E, Nebdal D, Git A, Caldas C, Børresen-Dale AL, Kleivi K (2019)
   miR-342-5p as a Potential Regulator of HER2 Breast Cancer Cell Growth
   Microrna, 8 (2), 155-165
   DOI 10.2174/2211536608666181206124922, PubMed 30520388
4. Lindholm EM, Ragle Aure M, Haugen MH, Kleivi Sahlberg K, Kristensen VN, Nebdal D, Børresen-Dale AL, Lingjaerde OC, Engebraaten O (2019)
   miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer
   Mol Oncol, 13 (10), 2278-2296
   DOI 10.1002/1878-0261.12561, PubMed 31402562
5. Madssen TS, Cao MD, Pladsen AV, Ottestad L, Sahlberg KK, Bathen TF, Giskeødegård GF (2019)
   Historical Biobanks in Breast Cancer Metabolomics- Challenges and Opportunities
   Metabolites, 9 (11)
   DOI 10.3390/metabo9110278, PubMed 31766128
6. Tekpli X, Lien T, Røssevold AH, Nebdal D, Borgen E, Ohnstad HO, Kyte JA, Vallon-Christersson J, Fongaard M, Due EU, Svartdal LG, Sveli MAT, Garred Ø, OSBREAC, Frigessi A, Sahlberg KK, Sørlie T, Russnes HG, Naume B, Kristensen VN (2019)
   An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment
   Nat Commun, 10 (1), 5499
   DOI 10.1038/s41467-019-13329-5, PubMed 31796750

Publications 2018

1. Tinholt M, Garred Ø, Borgen E, Beraki E, Schlichting E, Kristensen V, Sahlberg KK, Iversen N (2018)
   Subtype-specific clinical and prognostic relevance of tumor-expressed F5 and regulatory F5 variants in breast cancer: the CoCaV study
   J Thromb Haemost, 16 (7), 1347-1356
   DOI 10.1111/jth.14151, PubMed 29766637

Publications 2017

1. Aure MR, Vitelli V, Jernström S, Kumar S, Krohn M, Due EU, Haukaas TH, Leivonen SK, Vollan HK, Lüders T, Rødland E, Vaske CJ, Zhao W, Møller EK, Nord S, Giskeødegård GF, Bathen TF, Caldas C, Tramm T, Alsner J, Overgaard J, Geisler J, Bukholm IR, Naume B, Schlichting E et al. (2017)
   Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome
   Breast Cancer Res, 19 (1), 44
   DOI 10.1186/s13058-017-0812-y, PubMed 28356166
2. Cui XY, Skretting G, Tinholt M, Stavik B, Dahm AEA, Sahlberg KK, Kanse S, Iversen N, Sandset PM (2017)
   A novel hypoxia response element regulates oxygen-related repression of tissue factor pathway inhibitor in the breast cancer cell line MCF-7
   Thromb Res, 157, 111-116
   DOI 10.1016/j.thromres.2017.07.013, PubMed 28734156
3. Fleischer T, Tekpli X, Mathelier A, Wang S, Nebdal D, Dhakal HP, Sahlberg KK, Schlichting E, Oslo Breast Cancer Research Consortium (OSBREAC), Børresen-Dale AL, Borgen E, Naume B, Eskeland R, Frigessi A, Tost J, Hurtado A, Kristensen VN (2017)
   DNA methylation at enhancers identifies distinct breast cancer lineages
   Nat Commun, 8 (1), 1379
   DOI 10.1038/s41467-017-00510-x, PubMed 29123100
4. Jernström S, Hongisto V, Leivonen SK, Due EU, Tadele DS, Edgren H, Kallioniemi O, Perälä M, Mælandsmo GM, Sahlberg KK (2017)
   Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response
   Breast Cancer (Dove Med Press), 9, 185-198
   DOI 10.2147/BCTT.S115600, PubMed 28356768

Publications 2016

1. Cui XY, Tinholt M, Stavik B, Dahm AE, Kanse S, Jin Y, Seidl S, Sahlberg KK, Iversen N, Skretting G, Sandset PM (2016)
   Effect of hypoxia on tissue factor pathway inhibitor expression in breast cancer
   J Thromb Haemost, 14 (2), 387-96
   DOI 10.1111/jth.13206, PubMed 26598923
2. Haukaas TH, Euceda LR, Giskeødegård GF, Lamichhane S, Krohn M, Jernström S, Aure MR, Lingjærde OC, Schlichting E, Garred Ø, Due EU, Mills GB, Sahlberg KK, Børresen-Dale AL, Bathen TF, Oslo Breast Cancer Consortium (OSBREAC) (2016)
   Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes
   Cancer Metab, 4, 12
   DOI 10.1186/s40170-016-0152-x, PubMed 27350877
3. Nunes-Xavier CE, Karlsen KF, Tekle C, Pedersen C, Øyjord T, Hongisto V, Nesland JM, Tan M, Sahlberg KK, Fodstad Ø (2016)
   Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors
   Oncotarget, 7 (6), 6891-901
   DOI 10.18632/oncotarget.6902, PubMed 26771843
4. Tinholt M, Sandset PM, Mowinckel MC, Garred Ø, Sahlberg KK, Kristensen VN, Børresen-Dale AL, Jacobsen AF, Skretting G, Iversen N (2016)
   Determinants of acquired activated protein C resistance and D-dimer in breast cancer
   Thromb Res, 145, 78-83
   DOI 10.1016/j.thromres.2016.08.003, PubMed 27505249

Publications 2015

1. Aure MR, Jernström S, Krohn M, Vollan HK, Due EU, Rødland E, Kåresen R, Oslo Breast Cancer Research Consortium (OSBREAC), Ram P, Lu Y, Mills GB, Sahlberg KK, Børresen-Dale AL, Lingjærde OC, Kristensen VN (2015)
   Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer
   Genome Med, 7 (1), 21
   DOI 10.1186/s13073-015-0135-5, PubMed 25873999
2. Tinholt M, Vollan HK, Sahlberg KK, Jernström S, Kaveh F, Lingjærde OC, Kåresen R, Sauer T, Kristensen V, Børresen-Dale AL, Sandset PM, Iversen N (2015)
   Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF
   Breast Cancer Res, 17 (1), 44
   DOI 10.1186/s13058-015-0548-5, PubMed 25882602

Publications 2014

1. Hongisto V, Aure MR, Mäkelä R, Sahlberg KK (2014)
   The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells - A data description
   Genom Data, 2, 249-53
   DOI 10.1016/j.gdata.2014.06.025, PubMed 26484103
2. Kleivi Sahlberg K, Bottai G, Naume B, Burwinkel B, Calin GA, Børresen-Dale AL, Santarpia L (2014)
   A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients
   Clin Cancer Res, 21 (5), 1207-14
   DOI 10.1158/1078-0432.CCR-14-2011, PubMed 25547678
3. Nygren MK, Tekle C, Ingebrigtsen VA, Mäkelä R, Krohn M, Aure MR, Nunes-Xavier CE, Perälä M, Tramm T, Alsner J, Overgaard J, Nesland JM, Borgen E, Børresen-Dale AL, Fodstad Ø, Sahlberg KK, Leivonen SK (2014)
   Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c
   Br J Cancer, 110 (8), 2072-80
   DOI 10.1038/bjc.2014.113, PubMed 24577056
4. Tinholt M, Viken MK, Dahm AE, Vollan HK, Sahlberg KK, Garred O, Børresen-Dale AL, Jacobsen AF, Kristensen V, Bukholm I, Kåresen R, Schlichting E, Skretting G, Lie BA, Sandset PM, Iversen N (2014)
   Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study
   BMC Cancer, 14, 845
   DOI 10.1186/1471-2407-14-845, PubMed 25407022

Publications 2013

1. Aure MR, Leivonen SK, Fleischer T, Zhu Q, Overgaard J, Alsner J, Tramm T, Louhimo R, Alnæs GI, Perälä M, Busato F, Touleimat N, Tost J, Børresen-Dale AL, Hautaniemi S, Troyanskaya OG, Lingjærde OC, Sahlberg KK, Kristensen VN (2013)
   Individual and combined effects of DNA methylation and copy number alterations on miRNA expression in breast tumors
   Genome Biol, 14 (11), R126
   DOI 10.1186/gb-2013-14-11-r126, PubMed 24257477
2. Aure MR, Steinfeld I, Baumbusch LO, Liestøl K, Lipson D, Nyberg S, Naume B, Sahlberg KK, Kristensen VN, Børresen-Dale AL, Lingjærde OC, Yakhini Z (2013)
   Identifying in-trans process associated genes in breast cancer by integrated analysis of copy number and expression data
   PLoS One, 8 (1), e53014
   DOI 10.1371/journal.pone.0053014, PubMed 23382830
3. Hongisto V, Jernström S, Fey V, Mpindi JP, Kleivi Sahlberg K, Kallioniemi O, Perälä M (2013)
   High-throughput 3D screening reveals differences in drug sensitivities between culture models of JIMT1 breast cancer cells
   PLoS One, 8 (10), e77232
   DOI 10.1371/journal.pone.0077232, PubMed 24194875
4. Leivonen SK, Sahlberg KK, Mäkelä R, Due EU, Kallioniemi O, Børresen-Dale AL, Perälä M (2013)
   High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth
   Mol Oncol, 8 (1), 93-104
   DOI 10.1016/j.molonc.2013.10.001, PubMed 24148764
5. Tahiri A, Leivonen SK, Lüders T, Steinfeld I, Ragle Aure M, Geisler J, Mäkelä R, Nord S, Riis ML, Yakhini Z, Kleivi Sahlberg K, Børresen-Dale AL, Perälä M, Bukholm IR, Kristensen VN (2013)
   Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors
   Carcinogenesis, 35 (1), 76-85
   DOI 10.1093/carcin/bgt333, PubMed 24104550

Publications 2012

1. Sahlberg KK, Hongisto V, Edgren H, Mäkelä R, Hellström K, Due EU, Moen Vollan HK, Sahlberg N, Wolf M, Børresen-Dale AL, Perälä M, Kallioniemi O (2012)
   The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells
   Mol Oncol, 7 (3), 392-401
   DOI 10.1016/j.molonc.2012.10.012, PubMed 23253899

Publications 2011

1. Edgren H, Murumagi A, Kangaspeska S, Nicorici D, Hongisto V, Kleivi K, Rye IH, Nyberg S, Wolf M, Borresen-Dale AL, Kallioniemi O (2011)
   Identification of fusion genes in breast cancer by paired-end RNA-sequencing
   Genome Biol, 12 (1), R6
   DOI 10.1186/gb-2011-12-1-r6, PubMed 21247443
2. Enerly E, Steinfeld I, Kleivi K, Leivonen SK, Aure MR, Russnes HG, Rønneberg JA, Johnsen H, Navon R, Rødland E, Mäkelä R, Naume B, Perälä M, Kallioniemi O, Kristensen VN, Yakhini Z, Børresen-Dale AL (2011)
   miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors
   PLoS One, 6 (2), e16915
   DOI 10.1371/journal.pone.0016915, PubMed 21364938
3. Westbury CB, Sahlberg KK, Borresen-Dale AL, Isacke CM, Yarnold JR (2011)
   Gene expression profiling of human dermal fibroblasts exposed to bleomycin sulphate does not differentiate between radiation sensitive and control patients
   Radiat Oncol, 6, 42
   DOI 10.1186/1748-717X-6-42, PubMed 21521514

Publications 2010

1. Muggerud AA, Hallett M, Johnsen H, Kleivi K, Zhou W, Tahmasebpoor S, Amini RM, Botling J, Børresen-Dale AL, Sørlie T, Wärnberg F (2010)
   Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer
   Mol Oncol, 4 (4), 357-68
   DOI 10.1016/j.molonc.2010.06.007, PubMed 20663721
2. Rantala JK, Edgren H, Lehtinen L, Wolf M, Kleivi K, Vollan HK, Aaltola AR, Laasola P, Kilpinen S, Saviranta P, Iljin K, Kallioniemi O (2010)
   Integrative functional genomics analysis of sustained polyploidy phenotypes in breast cancer cells identifies an oncogenic profile for GINS2
   Neoplasia, 12 (11), 877-88
   DOI 10.1593/neo.10548, PubMed 21082043

Publications 2009

1. Leivonen SK, Mäkelä R, Ostling P, Kohonen P, Haapa-Paananen S, Kleivi K, Enerly E, Aakula A, Hellström K, Sahlberg N, Kristensen VN, Børresen-Dale AL, Saviranta P, Perälä M, Kallioniemi O (2009)
   Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines
   Oncogene, 28 (44), 3926-36
   DOI 10.1038/onc.2009.241, PubMed 19684618
2. Muggerud AA, Edgren H, Wolf M, Kleivi K, Dejeux E, Tost J, Sørlie T, Kallioniemi O (2009)
   Data integration from two microarray platforms identifies bi-allelic genetic inactivation of RIC8A in a breast cancer cell line
   BMC Med Genomics, 2, 26
   DOI 10.1186/1755-8794-2-26, PubMed 19432969

Publications 2007

1. Kleivi K, Lind GE, Diep CB, Meling GI, Brandal LT, Nesland JM, Myklebost O, Rognum TO, Giercksky KE, Skotheim RI, Lothe RA (2007)
   Gene expression profiles of primary colorectal carcinomas, liver metastases, and carcinomatoses
   Mol Cancer, 6, 2
   DOI 10.1186/1476-4598-6-2, PubMed 17201907

Publications 2006

1. Diep CB, Kleivi K, Ribeiro FR, Teixeira MR, Lindgjaerde OC, Lothe RA (2006)
   The order of genetic events associated with colorectal cancer progression inferred from meta-analysis of copy number changes
   Genes Chromosomes Cancer, 45 (1), 31-41
   DOI 10.1002/gcc.20261, PubMed 16145679
2. Kleivi K (2006)
   Advances in the genetics and epigenetics of gene regulation and human disease
   Genome Biol, 7 (8), 325
   DOI 10.1186/gb-2006-7-8-325, PubMed 16934107
3. Lind GE, Kleivi K, Meling GI, Teixeira MR, Thiis-Evensen E, Rognum TO, Lothe RA (2006)
   ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis
   Cell Oncol, 28 (5-6), 259-72
   DOI 10.1155/2006/949506, PubMed 17167179
4. Lind GE, Kleivi K, Meling GI, Teixeira MR, Thiis-Evensen E, Rognum TO, Lothe RA (2006)
   ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis
   Cell. Oncol., 28 (5-6), 259-272

Publications 2005

1. Kleivi K, Diep CB, Pandis N, Heim S, Teixeira MR, Lothe RA (2005)
   TP53 mutations are associated with a particular pattern of genomic imbalances in breast carcinomas
   J Pathol, 207 (1), 14-9
   DOI 10.1002/path.1812, PubMed 16007576

Publications 2004

1. Kleivi K, Teixeira MR, Eknaes M, Diep CB, Jakobsen KS, Hamelin R, Lothe RA (2004)
   Genome signatures of colon carcinoma cell lines
   Cancer Genet Cytogenet, 155 (2), 119-31
   DOI 10.1016/j.cancergencyto.2004.03.014, PubMed 15571797

Publications 2002

1. Kleivi K, Lothe RA, Heim S, Tsarouha H, Kraggerud SM, Pandis N, Papadopoulou A, Andersen J, Jakobsen KS, Teixeira MR (2002)
   Genome profiling of breast cancer cells selected against in vitro shows copy number changes
   Genes Chromosomes Cancer, 33 (3), 304-9
   DOI 10.1002/gcc.10032, PubMed 11807988